

References

Addiction Policy Forum. (2020). *How Common is Addiction?* [Video]. <https://www.addictionpolicy.org/post/how-common-is-addiction-1>

Addiction Policy Forum. (2020). DSM criteria for addiction simplified. <https://www.addictionpolicy.org/post/dsm-5-facts-and-figures>

Addiction Policy Forum (2020). *Addiction and the brain*. <https://addictionpolicy.org/post/addiction-and-the-brain>

Carroll, J. J., Rich, J. D., & Green, T. C. (2020). The protective effect of trusted dealers against opioid overdose in the U.S. *International Journal of Drug Policy*, 78, 102695.

Centers for Disease Control and Prevention. (2021, November 17). *Drug Overdose Deaths in the U.S. Top 100,000 Annually*. https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2021/20211117.htm

Irvine MA, Buxton JA, Otterstatter M, Balshaw R, Gustafson R, Tyndall M, Kendall P, Kerr T, Gilbert M, Coombs D. Distribution of take-home opioid antagonist kits during a synthetic opioid epidemic in British Columbia, Canada: a modelling study. *Lancet Public Health*. 2018 May;3(5):e218-e225. doi: 10.1016/S2468-2667(18)30044-6. Epub 2018 Apr 18. PMID: 29678561.

Koob, G. F. (2006). The neurobiology of addiction: A neuroadaptational view relevant for diagnosis. *Addiction*, 101, 23–30. <http://doi.org/10.1111/j.1360-0443.2006.01586.x>

Meinhofer A, Witman AE. (2018). The role of health insurance on treatment for opioid use disorders: Evidence from the Affordable Care Act Medicaid expansion. *J Health Econ*. 2018 Jul;60:177-197. doi: 10.1016/j.jhealeco.2018.06.004. Epub PMID: 29990675

National Institute on Drug Abuse. (2014). *Principles of drug abuse treatment for criminal justice populations: A research-based guide*. National Institutes of Health <https://www.drugabuse.gov/publications/principles-drug-abuse-treatment-criminal-justice-populations-research-based-guide/principles>

Petry N. M. (2011). Contingency management: What it is and why psychiatrists should want to use it. *The Psychiatrist*, 35(5), 161–163. <https://doi.org/10.1192/pb.bp.110.031831>

Reichert, J., Gleicher, L. (2019). Probation clients' barriers to access and use of opioid use disorder medications. *Health Justice* 7, 10. <https://doi.org/10.1186/s40352-019-0089-6>

Rhode Island Department of Health. (2018). Drug Overdose Prevention Program. https://health.ri.gov/programs/detail.php?pgm_id=1080

Saloner, B., Wilk, A. S., & Levin, J. (2020). Community health centers and access to care among underserved populations: a synthesis review. *Medical Care Research and Review*, 77(1), 3-18.

Saloner, B., Levin, J., Chang, H. Y., Jones, C., & Alexander, G. C. (2018). Changes in buprenorphine-naloxone and opioid pain reliever prescriptions after the Affordable Care Act Medicaid expansion. *JAMA network open*, 1(4), e181588-e181588.

SAMHSA. (2022). *Recovery and recovery support*. <https://www.samhsa.gov/recovery>

SAMHSA. (2015). *Co-occurring disorders in criminal justice settings*. <http://media.samhsa.gov/co-occurring/topics/criminal-justice/index.aspx>

Sharma, A., Kelly, S. M., Mitchell, S. G., Gryczynski, J., O'Grady, K. E., & Schwartz, R. P. (2017). Update on barriers to pharmacotherapy for opioid use disorders. *Current psychiatry reports*, 19, 1-8.

Sigmon, SC. (2014). Access to Treatment for Opioid Dependence in Rural America: Challenges and Future Directions. *JAMA Psychiatry*. 71(4):359–360. doi:10.1001/jamapsychiatry.2013.4450

Szlavitz, M. (2022). *Undoing drugs: The untold story of harm reduction and the future of addiction*. Hachette Go.

University of Washington. (2021). *Barriers to Treatment*. <https://adai.uw.edu/retentiontoolkit/barriers.htm>